GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-07-24|

Handheld Technology from Baxter Makes Diabetic Retinopathy Screening Simple and Affordable for Primary Care Settings

by GeneOnline
Share To
 

Early Detection Can Prevent 95% of Vision Loss Cases

SEOUL, South Korea, July 25, 2022 /PRNewswire/ — Diabetic retinopathy is the leading cause of blindness among working-age adults globally.1 With early detection and treatment, as much as 95 percent of vision loss cases can be prevented.2 Compliance with annual diabetic retinal exams in South Korea was found to be approximately 53%, with only 73% of those taking place in the last 12 months.3  Up to 80% of individuals with type two diabetes may eventually develop some stage of diabetic retinopathy.4

The Welch Allyn® RetinaVue™ 100 Imager PRO enables diabetic retinopathy screening in primary care settings. By quickly and comfortably screening patients as part of their routine primary care visit, it has been shown that RetinaVue can double patient compliance for potentially vision-saving annual diabetic retinal exams (DREs) in 12 months.5

“Diabetes is an epidemic. Diabetic retinopathy is the leading cause of vision loss among adults 20-to-74 years of age,6 affecting 7.7 million people worldwide.7 It is simply tragic that a large percentage of patients with diabetes aren’t being screened for diabetic retinopathy, when it’s one of the most preventable causes of blindness among adults,” said Bruce Peatey, Vice President of Baxter, Asia Pacific. “RetinaVue has the potential to change lives by helping to identify diabetic retinopathy in those individuals who had not previously been screened for the disease, enhancing the potential to save the sight of thousands, if not millions, of people with diabetes.”

Baxter makes this possible by reducing the cost barrier for high-quality fundus imaging. The RetinaVue 100 Imager PRO costs  significantly less than full-size fundus cameras, yet the imager is designed such that any healthcare professional in a primary care practice can capture high-quality fundus images with minimal training.

With nonmydriatic capture through a 3.0mm pupil, the RetinaVue 100 Imager PRO enables comfortable exams without pharmacologic dilation. The handheld, portable device is an attractive solution for mobility across multiple locations. The solution utilizes proprietary touchless auto-focus/image-capture technology and integrated image-quality assessment algorithms, which can help reduce your need for re-imaging appointments. You will get an immediate quality score on the image you capture.

The device will be available in South Korea beginning July 25, 2022. Through RetinaVue, Baxter is committed to delivering simple and affordable screening solutions to help save vision for patients living with diabetes in primary care. For more information, please visit www.baxter.com or  https://www.hillrom.kr/ko/solutions/combating-chronic-disease-apac/Diabetic-Retinopathy/

1. Diabetic Retinopathy | Fred Hollows Foundation

2. Facts About Diabetic Eye Disease; The National Eye Institute (NEI); https://nei.nih.gov/health/diabetic/retinopathy 

3. https://drbarometer.com/docs/default-source/dr-barometer-study-finding-documents/countries/south-korea/dr-barometer-south-korea-report.pdf?sfvrsn=e1f0cfdf_2 PAGE 134.

4. Lee DJ, Kumar N, Feuer WJ, et al. BMJ Open Diabetes Res Care. 2014;2(1):e000031.

5. Telemedicine and Retinal Imaging for Improving Diabetic Retinopathy Evaluation; Archives of Internal Medicine; Vol.172, Num. 21, 2012

6. Updated: Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated September 29, 2015. Accessed January 30, 2020.

7. National Eye Institute. Diabetic Retinopathy Data and Statistics. https://www.nei.nih.gov/learn-about-eye-health/resources-for-health-educators/eye-health-data-and-statistics/diabetic-retinopathy-data-and-statistics Published July 17, 2019. Updated July 17, 2019. Accessed February 24, 2020.

About Baxter 

Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

CONTACT INFORMATION

Investor Relations

 

Media

         

Contact:

 

Clare Trachtman,

Vice President,
Investor Relations

Contact: 

Bella Ling, Senior Director of

Communications,

APAC & Greater China

       

Phone:

312-819-9387

 

Phone:

+86 136 4196 2389

       

Email:

[email protected]  

 Email: 

[email protected]

       

 

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
2025-01-10
United Imaging Announces Major Expansion of U.S. Manufacturing Space
2025-01-09
Complete Genomics announces mpox virus amplicon sequencing panel at AMP
2024-11-20
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top